- Open
- 4.65
- High
- 4.79
- Low
- 4.43
- Close
- 4.43
- Change
- -0.25 (-5.38%)
- Volume
- 1,321,321
| 1 Sept 2026 | 07:00:14 | Total Voting Rights |
| 27 Aug 2026 | 16:00:00 | Shield assumes full control of ACCRUFeR® in the US |
| 20 Aug 2026 | 07:00:06 | Interim results for the six months ended 30 Jun 26 |
| 3 Aug 2026 | 12:02:21 | Total Voting Rights |
| 30 Jul 2026 | 07:00:04 | Q2 and H1 2026 Trading Update |
| 25 Jun 2026 | Shield Therapeutics plc 2025 Annual Report and Accounts | |
| 29 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) |
Shield Therapeutics PLC is a specialty pharmaceutical company focused on addressing iron deficiency. It develops and commercializes ACCRUFeR®, a non-salt based oral treatment for adults with iron deficiency, regardless of anaemia status. The company operates through partnerships, primarily with Viatris, to drive prescription demand and optimize distribution channels in the U.S. Shield is also expanding its product indications to include children and supports global licensing partners in various markets, including Japan, South Korea, China, Canada, and Europe.
| 1 Sept 2026 | 07:00:14 | Total Voting Rights |
| 27 Aug 2026 | 16:00:00 | Shield assumes full control of ACCRUFeR® in the US |
| 20 Aug 2026 | 07:00:06 | Interim results for the six months ended 30 Jun 26 |
| 3 Aug 2026 | 12:02:21 | Total Voting Rights |
| 30 Jul 2026 | 07:00:04 | Q2 and H1 2026 Trading Update |
| 25 Jun 2026 | Shield Therapeutics plc 2025 Annual Report and Accounts | |
| 29 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 6 Jun 2025 | Annual Report and Accounts (to 2024-12-31) |
Shield Therapeutics PLC is a specialty pharmaceutical company focused on addressing iron deficiency. It develops and commercializes ACCRUFeR®, a non-salt based oral treatment for adults with iron deficiency, regardless of anaemia status. The company operates through partnerships, primarily with Viatris, to drive prescription demand and optimize distribution channels in the U.S. Shield is also expanding its product indications to include children and supports global licensing partners in various markets, including Japan, South Korea, China, Canada, and Europe.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £187.58bn | +0.0% | |
| £3.26bn | -0.1% | |
| £274m | -0.1% | |
| £64m | +0.3% | |
| £62m | -0.3% | |
STXShield Therapeutics PLC | £47m | -0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £187.58bn | +0.0% | |
| £3.26bn | -0.1% | |
| £274m | -0.1% | |
| £64m | +0.3% | |
| £62m | -0.3% | |
STXShield Therapeutics PLC | £47m | -0.5% |